Solid Biosciences (SLDB) to Release Quarterly Earnings on Thursday

Solid Biosciences (NASDAQ:SLDB - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 15th. Analysts expect Solid Biosciences to post earnings of ($0.53) per share for the quarter.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). On average, analysts expect Solid Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Solid Biosciences Price Performance

Shares of NASDAQ:SLDB traded up $0.13 during mid-day trading on Monday, reaching $2.90. 1,599,220 shares of the company were exchanged, compared to its average volume of 1,051,453. The firm has a market cap of $224.76 million, a price-to-earnings ratio of -0.95 and a beta of 2.32. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The firm's 50-day simple moving average is $3.46 and its 200 day simple moving average is $4.18.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Piper Sandler reduced their target price on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday. Wedbush reduced their target price on shares of Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday. HC Wainwright increased their target price on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Cantor Fitzgerald upgraded shares of Solid Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Chardan Capital reduced their target price on shares of Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Monday. Nine investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Solid Biosciences presently has an average rating of "Buy" and a consensus price target of $14.78.

Institutional Investors Weigh In On Solid Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Woodline Partners LP acquired a new stake in shares of Solid Biosciences in the 1st quarter valued at $2,338,000. Goldman Sachs Group Inc. grew its position in shares of Solid Biosciences by 32.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company's stock valued at $667,000 after buying an additional 43,910 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Solid Biosciences in the 1st quarter valued at $418,000. 81.46% of the stock is currently owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.